Amgen sues Samsung biotech unit over bone drug copies
By Blake Brittain
Aug 13 (Reuters) -Amgen AMGN.O has sued Samsung's biologics unit 207940.KS in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster bone drugs Prolia and Xgeva.
Amgen's lawsuit against Samsung Bioepis, filed on Monday, said the biosimilars would infringe 34 patents covering Amgen drugs. It requested an order blocking Samsung from making and selling the drugs and an unspecified amount of monetary damages.
Spokespeople for Amgen and Samsung Bioepis did not immediately respond to requests for comment on the complaint on Tuesday.
Biosimilars are versions of biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs are made from living cells and cannot be copied exactly.
Thousand Oaks, California-based Amgen told the court on Monday that Samsung had applied for permission from the U.S. Food and Drug Administration to market biosimilars of Prolia, which treats patients suffering from osteoporosis and others at high risk for bone breaks, and Xgeva, which prevents fractures in bone-cancer patients.
Amgen sold more than $2.7 billion worth of Prolia and $1.5 billion of Xgeva in the United States last year, according to a company report. The FDA granted approval in March for Sandoz to market the first biosimilars of the drugs, which will be available in the U.S. by May 2025 following the settlement of a separate patent dispute between Sandoz and Amgen.
Amgen told the court that Samsung's biosimilars would infringe patents covering Prolia and Xgeva's active ingredient denosumab and other technology related to the drugs.
The case is Amgen Inc v. Samsung Bioepis Co, U.S. District Court for the District of New Jersey, No. 1:24-cv-08417.
For Amgen: Steven Horowitz, Nathaniel Love, David Anderson, Sue Wang, Jeffrey Kushan, Joshua Fougere, Lauren Katzeff and Samuel Tiu of Sidley Austin; Siegmund Gutman and David Hanna of Mintz Levin Cohn Ferris Glovsky & Popeo
For Samsung: attorney information not yet available
Reporting by Blake Brittain in Washington
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
